1. Home
  2. SRPT vs REVBW Comparison

SRPT vs REVBW Comparison

Compare SRPT & REVBW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SRPT
  • REVBW
  • Stock Information
  • Founded
  • SRPT 1980
  • REVBW N/A
  • Country
  • SRPT United States
  • REVBW United States
  • Employees
  • SRPT N/A
  • REVBW 9
  • Industry
  • SRPT Biotechnology: Pharmaceutical Preparations
  • REVBW Biotechnology: Pharmaceutical Preparations
  • Sector
  • SRPT Health Care
  • REVBW Health Care
  • Exchange
  • SRPT Nasdaq
  • REVBW Nasdaq
  • Market Cap
  • SRPT N/A
  • REVBW N/A
  • IPO Year
  • SRPT 1997
  • REVBW 2020
  • Fundamental
  • Price
  • SRPT $110.10
  • REVBW $0.02
  • Analyst Decision
  • SRPT Buy
  • REVBW
  • Analyst Count
  • SRPT 22
  • REVBW 0
  • Target Price
  • SRPT $174.64
  • REVBW N/A
  • AVG Volume (30 Days)
  • SRPT 891.1K
  • REVBW N/A
  • Earning Date
  • SRPT 02-26-2025
  • REVBW N/A
  • Dividend Yield
  • SRPT N/A
  • REVBW N/A
  • EPS Growth
  • SRPT N/A
  • REVBW N/A
  • EPS
  • SRPT 1.22
  • REVBW N/A
  • Revenue
  • SRPT $1,640,348,000.00
  • REVBW N/A
  • Revenue This Year
  • SRPT $52.33
  • REVBW N/A
  • Revenue Next Year
  • SRPT $69.75
  • REVBW N/A
  • P/E Ratio
  • SRPT $91.67
  • REVBW N/A
  • Revenue Growth
  • SRPT 48.45
  • REVBW N/A
  • 52 Week Low
  • SRPT $102.16
  • REVBW N/A
  • 52 Week High
  • SRPT $173.25
  • REVBW N/A
  • Technical
  • Relative Strength Index (RSI)
  • SRPT 39.04
  • REVBW N/A
  • Support Level
  • SRPT $111.48
  • REVBW N/A
  • Resistance Level
  • SRPT $120.05
  • REVBW N/A
  • Average True Range (ATR)
  • SRPT 3.52
  • REVBW 0.00
  • MACD
  • SRPT -0.26
  • REVBW 0.00
  • Stochastic Oscillator
  • SRPT 6.59
  • REVBW 0.00

About REVBW Revelation Biosciences Inc. Warrant

Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

Share on Social Networks: